Restoring physiology in iron-deficient organisms using small molecules

Abstract

Provided are methods of treating a disease or condition characterized by a deficiency of or a defect in an iron transporter using a small molecule. For example, the method may increase transepithelial iron transport, or it may increase iron release. Additionally, the small molecule may be hinokitiol, or it may be selected from the group consisting of amphotericin B, calcimycin, nonactin, deferiprone, purpurogallin, and maltol. Also provided is a method of identifying a compound capable of treating a disease or condition characterized by a deficiency of or a defect in an iron transporter.

1 - 2 . (canceled) 
     
     
         3 . A method of increasing transepithelial iron transport in a subject in need thereof, comprising administering to the subject an effective amount of a small molecule. 
     
     
         4 . (canceled) 
     
     
         5 . A method of increasing hemoglobinization in a subject in need thereof, comprising administering to the subject an effective amount of a small molecule. 
     
     
         6 . A method of increasing iron release in a subject in need thereof, comprising administering to the subject an effective amount of a small molecule. 
     
     
         7 . The method of  claim 3 , wherein the small molecule is selected from the group consisting of amphotericin B (AmB), calcimycin, nonactin, deferiprone, purpurogallin, and maltol, and any combination thereof. 
     
     
         8 . (canceled) 
     
     
         9 . The method of  claim 3 , wherein the small molecule is hinokitiol. 
     
     
         10 . The method of  claim 3 , wherein the small molecule is administered systemically, orally, or intraveneously. 
     
     
         11 - 12 . (canceled) 
     
     
         13 . The method of  claim 3 , wherein the subject is a mammal. 
     
     
         14 . The method of  claim 13 , wherein the subject is a human. 
     
     
         15 . The method of  claim 3 , wherein the subject is deficient in divalent metal transporter 1 (DMT1). 
     
     
         16 - 23 . (canceled) 
     
     
         24 . The method of  claim 5 , wherein the small molecule is selected from the group consisting of amphotericin B (AmB), calcimycin, nonactin, deferiprone, purpurogallin, and maltol, and any combination thereof 
     
     
         25 . The method of  claim 5 , wherein the small molecule is hinokitiol. 
     
     
         26 . The method of  claim 5 , wherein the small molecule is administered systemically, orally, or intraveneously. 
     
     
         27 . The method of  claim 5 , wherein the subject is a mammal. 
     
     
         28 . The method of  claim 27 , wherein the subject is a human. 
     
     
         29 . The method of  claim 5 , wherein the subject is deficient in divalent metal transporter 1 (DMT1). 
     
     
         30 . The method of  claim 6 , wherein the small molecule is selected from the group consisting of amphotericin B (AmB), calcimycin, nonactin, deferiprone, purpurogallin, and maltol, and any combination thereof 
     
     
         31 . The method of  claim 6 , wherein the small molecule is hinokitiol. 
     
     
         32 . The method of  claim 6 , wherein the small molecule is administered systemically, orally, or intraveneously. 
     
     
         33 . The method of  claim 6 , wherein the subject is a mammal. 
     
     
         34 . The method of  claim 6 , wherein the subject is deficient in divalent metal transporter 1 (DMT1).